These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 7859803

  • 21. Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations.
    Reyes AJ, Leary WP.
    Cardiovasc Drugs Ther; 1993 Jan; 7 Suppl 1():29-44. PubMed ID: 8435375
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics and pharmacodynamics of torasemide in congestive heart failure.
    Kramer WG.
    Cardiology; 1994 Jan; 84 Suppl 2():108-14. PubMed ID: 7954532
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites.
    Engelhardt S, Meineke I, Brockmöller J.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb 02; 831(1-2):31-5. PubMed ID: 16344009
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Update: prolonged-release torasemide].
    Acuña C.
    Drugs Today (Barc); 2010 Jul 02; 46 Suppl E():1-15. PubMed ID: 20882198
    [Abstract] [Full Text] [Related]

  • 28. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.
    Werner D, Werner U, Meybaum A, Schmidt B, Umbreen S, Grosch A, Lestin HG, Graf B, Zolk O, Fromm MF.
    Clin Pharmacokinet; 2008 Jul 02; 47(5):323-32. PubMed ID: 18399713
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Benefits and risks of torasemide in congestive heart failure and essential hypertension.
    Brater DC.
    Drug Saf; 1996 Feb 02; 14(2):104-20. PubMed ID: 8852525
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Failure of indomethacin to impair the diuretic and natriuretic effects of the loop diuretic torasemide in healthy volunteers.
    van Ganse E, Douchamps J, Deger F, Staroukine M, Verniory A, Herchuelz A.
    Eur J Clin Pharmacol; 1986 Feb 02; 31 Suppl():43-7. PubMed ID: 3536531
    [Abstract] [Full Text] [Related]

  • 35. Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide.
    Kim YC, Lee MG, Ko SH, Kim SH.
    J Pharm Pharmacol; 2003 Nov 02; 55(11):1515-22. PubMed ID: 14713362
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Interaction of the diuretics torasemide and U-37883A with the K(ATP) channel in rat isolated aorta.
    Löffler-Walz C, Quast U.
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug 02; 358(2):230-7. PubMed ID: 9750009
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study.
    Scheen AJ, Vancrombreucq JC, Delarge J, Luyckx AS.
    Eur J Clin Pharmacol; 1986 Aug 02; 31 Suppl():35-42. PubMed ID: 3780838
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.